Supernus Pharmaceuticals, Inc. $SUPN Shares Acquired by First Trust Advisors LP

First Trust Advisors LP lifted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 56.4% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 46,627 shares of the specialty pharmaceutical company’s stock after acquiring an additional 16,823 shares during the period. First Trust Advisors LP owned approximately 0.08% of Supernus Pharmaceuticals worth $2,410,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. PNC Financial Services Group Inc. raised its position in shares of Supernus Pharmaceuticals by 2.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company’s stock valued at $752,000 after purchasing an additional 321 shares during the last quarter. Summit Global Investments grew its position in Supernus Pharmaceuticals by 6.1% during the 1st quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock worth $229,000 after purchasing an additional 256 shares during the last quarter. Swiss National Bank grew its position in Supernus Pharmaceuticals by 2.6% during the 1st quarter. Swiss National Bank now owns 113,500 shares of the specialty pharmaceutical company’s stock worth $5,867,000 after purchasing an additional 2,900 shares during the last quarter. Assetmark Inc. increased its stake in Supernus Pharmaceuticals by 6.2% during the 1st quarter. Assetmark Inc. now owns 43,972 shares of the specialty pharmaceutical company’s stock valued at $2,273,000 after purchasing an additional 2,578 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in Supernus Pharmaceuticals by 11.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,390 shares of the specialty pharmaceutical company’s stock valued at $329,000 after purchasing an additional 649 shares in the last quarter.

Wall Street Analyst Weigh In

Several research firms have recently commented on SUPN. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Cantor Fitzgerald lifted their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $62.83.

Supernus Pharmaceuticals Trading Up 1.9%

SUPN opened at $47.64 on Friday. Supernus Pharmaceuticals, Inc. has a 12-month low of $40.26 and a 12-month high of $59.68. The firm has a 50 day moving average of $46.17 and a two-hundred day moving average of $48.93. The firm has a market capitalization of $2.77 billion, a PE ratio of -24.81, a P/E/G ratio of 0.76 and a beta of 0.56.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.